End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.24 USD | -5.02% |
|
-4.04% | +133.08% |
06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
06-12 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.